Requires physician to offer to test patient for dihydropyrimidine dehydrogenase deficiency prior to patient undergoing chemotherapy.

This bill requires New Jersey physicians to offer patients a test for dihydropyrimidine dehydrogenase deficiency (a condition that can cause dangerous reactions to chemotherapy drugs) before starting chemotherapy. It directly affects patients scheduled for chemotherapy in New Jersey, ensuring they can be screened for this specific risk. The bill mandates that all health insurance policies sold in New Jersey must cover one annual test for this deficiency and any related treatment, at the same level as other medical conditions. This applies to individual, group, and other health insurance plans in the state, with coverage required for both the test and prescribed treatments. The goal is to prevent severe adverse reactions by identifying patients at risk before chemotherapy begins.